Efficacy of 10‐day Sitafloxacin‐Containing Third‐Line Rescue Therapies for <i>Helicobacter pylori</i> Strains Containing the <i>gyrA</i> Mutation

Abstract

There is no significant difference in the eradication rates between EAS and EMS, regardless of the gyrA mutation status of the H. pylori strains. GyrA mutation status was an important factor in predicting successful eradication with sitafloxacin-containing rescue therapies.